Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma

Molecular Cancer Therapeutics

Volumn 7, Issue 7, 2008, Pages 1807-1816

  Guan, Hui ^a   Zhou, Zhichao ^a   Gallick, Gary E ^a   Jia, Shu Fang ^a   Morales, Jaime ^a   Sood, Anil K ^a   Corey, Seth J ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AP 23994; HYBRID PROTEIN; POLYETHYLENEIMINE; PROTEIN KINASE LYN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RNA BINDING PROTEIN EWS PLUS TRANSCRIPTION FACTOR FLI 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; CADHERIN; LYN PROTEIN-TYROSINE KINASE; OSTEOBLAST CADHERIN; TRANSCRIPTION FACTOR FLI 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER TISSUE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; EWING SARCOMA; GENE EXPRESSION; GENE THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TISSUE SECTION; TUMOR REGRESSION; ANIMAL; BONE TUMOR; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG SCREENING; ENZYMOLOGY; LUNG TUMOR; METABOLISM; NUDE MOUSE; OSTEOLYSIS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BONE NEOPLASMS; BONE RESORPTION; CADHERINS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEIN C-FLI-1; SARCOMA, EWING'S; SRC-FAMILY KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 51049114726     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0058     Document Type: Article

References (41)

1. Delattre O, Zucman J, Plougastel B, et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-5.
2. Mirra JM, Picci P, Gold RH, Goorin AM. Bone tumors: clinical, radiological and pathological correlation. Philadelphia: Lea & Febiger; 1989. p. 1087-117.
3. Dorfman HD, Czerniak B. Bone tumors. St. Louis: Mosby; 1998. p. 607-49.
4. Avigad S, Yaniv I. Novel approaches for the management of patients with Ewing sarcoma. Future Oncol 2006;2:659-65.
5. Riggi N, Stamenkovic I. The biology of Ewing sarcoma. Cancer Lett 2007;254:1-10.
6. Scotlandi K. Targeted therapies in Ewing's sarcoma. Adv Exp Med Biol 2006;587:13-22.
7. Roginskaya V, Zuo S, Caudell E, et al. Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia 1999;13:855-61.
8. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690-8.
9. Ptasznik A, Nakata Y, Kalota A, Emerson SG, Gewirtz AM. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells. Nat Med 2004;10:1187-9.
10. Harder KW, Parsons LM, Armes J, et al. Gain- and loss-of-function Lyn mutant mice define a critical inhibitory role for Lyn in the myeloid lineage. Immunity 2001;15:603-15.
11. Goldenberg-Furmanov M, Stein I, Pikarsky E, et al. Lyn is a target gene for prostate cancer: sequence-based inhibition induces regression of human tumor xenografts. Cancer Res 2004;64:1058-66.
12. Stettner MR, Wang W, Nabors LB, et al. Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells. Cancer Res 2005;65:5535-43.
13. Fu Y, Zagozdzon R, Avraham R, Avraham HK. CHK negatively regulates Lyn kinase and suppresses pancreatic cancer cell invasion. Int J Oncol 2006;29:1453-8.
14. Bates RC, Edwards NS, Burns GF, Fisher DE. A CD44 survival pathway triggers chemoresistance via Lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res 2001;61:5275-83.
15. Rosen N, Bolen JB, Schwartz AM, et al. Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J Biol Chem 1986;261:13754-9.
16. Shor AC, Keschman EA, Lee FY, et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 2007;67:2800-8.
17. Guan H, Zhou Z, Wang H, et al. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res 2005;11:2662-9.
18. Ding Q, Stewart J, Olman MA, Klobe MR, Gladson CL. The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged. J Biol Chem 2003;278:39882-91.
19. Takahashi A, Higashino F, Aoyagi M, et al. EWS/ETS fusions activate telomerase in Ewing's tumors. Cancer Res 2003;63:8338-44.
20. Jia SF, Worth LL, Densmore CL, Xu B, Zhou Z, Kleinerman ES. Eradication of osteosarcoma lung metastases following intranasal interleukin-12 gene therapy using a nonviral polyethylenimine vector. Cancer Gene Ther 2002;9:260-6.
21. Weber KL, Doucet M, Price JE, Baker C, Kim SJ, Fidler IJ. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res 2003;63:2940-7.
22. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003;22:337-58.
23. Halbleib JM, Nelson WJ. Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev 2006;20:3199-214.
24. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 2004;4:118-32.
25. Han LY, Landen CN, Trevino JG, et al. Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma. Cancer Res 2006;66:8633-9.
26. Prakash O, Swamy OR, Peng X, et al. Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis. Blood 2005;105:3987-94.
27. Hibbs ML, Tarlinton DM, Armes J, et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995;83:301-11.
28. Chan VW, Meng F, Soriano P, DeFranco AL, Lowell CA. Characterization of the B lymphocyte populations in Lyn-deficient mice and the role of Lyn in signal initiation and down-regulation. Immunity 1997;7:69-81.
29. Katagiri K, Yokoyama KK, Yamamoto T, et al. Lyn and Fgr protein-tyrosine kinases prevent apoptosis during retinoic acid-induced granulocytic differentiation of HL-60 cells. J Biol Chem 1996;271:11557-62.
30. Daigle I, Yousefi S, Colonna M, Green DR, Simon HU. Death receptors bind SHP-1 and block cytokine-induced anti-apoptotic signaling in neutrophils. Nat Med 2002;8:61-7.
31. Hibbs ML, Harder KW. The duplicitous nature of the Lyn tyrosine kinase in growth factor signaling. Growth Factors 2006;24:137-49.
32. Nikolic DM, Cholewa J, Gass C, Gong MC, Post SR. Class A scavenger receptor-mediated cell adhesion requires the sequential activation of Lyn and PI3-kinase. Am J Physiol Cell Physiol 2007;292:C1450-8.
33. Udell CM, Samayawardhena LA, Kawakami Y, et al. Fer and Fps/Fes participate in a Lyn-dependent pathway from FcεRI to platelet-endothelial cell adhesion molecule 1 to limit mast cell activation. J Biol Chem 2006;281:20949-57.
34. Nam S, Kim D, Cheng JQ, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005;65:9185-9.
35. + marrow cells. Blood 2006;107:4234-9.
36. Munshi HG, Stack MS. Reciprocal interactions between adhesion receptor signaling and MMP regulation. Cancer Metastasis Rev 2006;25:45-56.
37. Boyce BF, Xing L, Yao Z, et al. SRC inhibitors in metastatic bone disease. Clin Cancer Res 2006;12:s6291-5.
38. Tanaka K, Iwakuma T, Harimaya K, Sato H, Iwamoto Y. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 1997;99:239-47.
39. Kovar H, Aryee DN, Jug G, et al. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 1996;7:429-37.
40. Ohno T, Rao VN, Reddy ES. EWS/Fli-1 chimeric protein is a transcriptional activator. Cancer Res 1993;53:5859-63.
41. Welford SM, Hebert SP, Deneen B, Arvand A, Denny CT. DNA binding domain-independent pathways are involved in EWS/FLI1-mediated oncogenesis. J Biol Chem 2001;276:41977-84.